1. Introduction

Although cancer treatments have undergone massive developments in recent years, cancer remains a difficult disease to solve worldwide. Traditional cancer therapies, such as clinical operation, chemotherapy, and radiotherapy, may have a curative effect in the short term but will cause side effects, decreasing cancer patient quality of life [1]. Immunotherapy has been recognized as a new generation of an antitumor weapon and will be the leading force in future cancer treatment. Immunotherapy is a kind of therapy that targets the human immune system rather than directly targeting tumors. It can resist and kill tumor cells by activating patient defenses [2]. Adoptive cell transfer therapy (ACT) is an immunotherapy that separates immunocompetent cells from cancer patients and transfers them to patients after expansion or functional identification in vitro; adaptive cells kill tumor cells directly or stimulate the body’s immune response [3].

ACT can be roughly divided into three forms. (1) Tumor-infiltrating lymphocytes (TILs) are lymphocytes that infiltrate the tumor cell stroma, and after IL-2 activation, they have a stronger antitumor effect. While melanoma patients showed a remarkable clinical response by TILs, TIL treatment was not as effective in other tumors, such as renal cell carcinoma [4, 5]. (2) T cell receptor- (TCR-) T cells are heterodimeric proteins composed of two structural domains: TCRα and TCRβ. TCR-T cells activate cytotoxicity and release cytokines to inhibit the proliferation of cancer cells specifically or kill cancer cells by explicitly recognizing the assembly, modification and processing of specific proteins in cancer cells via cancer-specific major histocompatibility complex (MHC) molecules [6, 7]. TCR-T cells can target most tumor-specific antigens, particularly those that can rec-
ognize the tumor cell antigen. Thus, TCR-T cells can recognize a broader range of antigens than the tumor antibody drugs [4, 8]. (3) Chimeric antigen receptor- (CAR-) T cells are composed of extracellular, transmembrane, and intracellular domains. The extracellular domain has an scFv domain for the recognition of tumor-associated antigens with specificity and affinity. The intracellular domain is derived from the immunoreceptor tyrosine-based activation motif (ITAM) of the TCR complex CD3ζ chain, which activates the costimulatory signal. CAR-T cells are manufactured by generating a single-chain variable fragment (scFv) that recognizes tumor-associated antigen (TAA) recombinants and an intracellular, recombinant “immunoreceptor tyrosine activation motif” (ITAM) region, which are incorporated into a recombinant plasmids in vitro. Subsequently, the recombinant plasmid is transduced into T cells, allowing T cells to express the appropriate tumor surface antigen receptors, and T cells are expanded after transfection. CAR-T cells recognize and kill tumor cells independent of major histocompatibility complex (MHC) molecules; thus, immune escape of tumor cells overcome by the decreased expression of MHC molecules. However, CAR-T cells can recognize tumor antigens only when they are specifically expressed on the surface of cell membranes; thus, the target is very specific [9].

To develop the best CAR-T cells, four generations of CAR-T cells have been created via continuous exploration and improvement of the effects of intracellular signaling domains (Figure 1). The first generation of CAR-T cells includes an scFv antigen-binding epitope with one signaling domain. The CD3ζ chain activates the first generation of CAR-T cells. The CD3ζ chain provides the signals required for T cell activation, lysis of target cells, regulation of IL-2 secretion, and antitumor immunoregulatory activity. However, the antitumor action of the first-generation CAR-T cells was limited in vivo, and the decrease in T cell proliferation ultimately led to the apoptosis of T cells [10, 11]. The second-generation CAR-T cells add an additional costimulatory signal to the cells. The commonly used costimulatory molecule is CD28 or the 4-1BB receptor (CD137). Many studies have shown that the second-generation CAR-T cells have no specific antigen, and compared with the those of first-generation CAR-T cells, second-generation CAR-T cell proliferation, cytokine secretion, and secretion of antiapoptotic proteins are increased, and the second-generation cells lead to delayed antigen-induced cell death [8]. To further improve the design of CAR-T cells, many research groups began to focus on the development of third-generation CAR-T cells. Wilkie et al. showed that there was no significant difference in antitumor cytotoxicity between second-generation CAR-T cells and third-generation CAR-T cells incorporating the 4-1BB and CD28 signaling domains, although T cells expressing the third-generation CAR-T cells were able to secrete larger amounts of IFN-γ than those with first-generation or second-generation CAR-T cell [12]. Some studies have shown that CD28 exhibits improved antitumor activity, and the advantage of 4-1BB is to prolong the survival of T cells and maintain their anticancer effects. However, recent results show that only the second-generation CAR-T cells can activate CD3ζ, and second-generation CAR-T cells have stronger signal transduction and antitumor effects than third-generation CAR-T cells [13]. Fourth-generation CAR-T cells are also known as T cells redirected for

Figure 1: The development and design principle of CAR-T three generations. The first generation of CAR-T cells was composed of immunoglobulin scFv and CD3 complexes. Most of the experiments did not respond well in cell expansion, in vivo survival time, cytokine secretion, etc., and the therapeutic effect was not as expected. The second- and third-generation CARs add costimulatory molecules such as CD28, CD134, and CD137 (4-1BB) to the chimeric receptor, which enables the cells to obtain long-lasting in vitro proliferation ability and strong cytokine secretion ability. The fourth generation of CAR-T can solve the problem that traditional CAR-T cannot identify and remove some antigens that are not explicitly recognized by T cells.
universal cytokine killing (TRUCK). Unlike earlier generation of CAR-T cells, these CAR-T cells can identify and remove some antigens that are not recognized explicitly by T cells. The fourth-generation CAR-T cells contain an activated T cell nuclear factor transcriptional counterpart that allows them to secrete specific cytokines (e.g., IL-12) in the tumor, thereby modifying the tumor microenvironment and recruiting and activating other the immune cells to generate an immune response.

2. Potential Mechanisms of CAR-T Cell-Mediated Toxicity

Significant progress has been made in the field of cancer immunotherapy, and CAR-T cells have shown outstanding efficacy in clinical trials. As with all technologies, CAR-T technologies also need to go through a long process of development, and CAR-T cell therapy has related acute and chronic toxicities that have become a roadblock on the developmental path (Figure 2). If these setbacks are not overcome, it will be difficult to make a more significant breakthrough. However, these barriers also represent opportunities in this field [14].

2.1. Cytokine Release Syndrome. Cytokine release syndrome (CRS) is the most common toxic side effect in CAR-T cell therapy [15]. CRS is a systemic inflammatory response caused by the significant increase in cytokines accompanied by the rapid in vivo activation and proliferation of CAR-T cells, usually occurring within a few days after the first infusion [3, 16]. CRS is a clinical condition with mild symptoms of fever, fatigue, headache, rash, joint pain, and myalgia. Severe CRS cases are characterized by tachycardia, hypotension, and high fever [17, 18]. Mild to moderate CRS is usually self-limiting and can be managed through close observation and supportive care. Severe CRS must be treated with tocilizumab or steroids alone for intensive treatment. However, there are still cases in which the clinical symptoms are not improved or aggravated after intensive treatment [19]. CRS is caused by excessive inflammatory cytokines as a result of hyperimmune activation. Indeed, the detailed pathogenesis is not yet clear. However, recent discoveries have revealed the underlying mechanisms of CAR-T cell-induced CRS. After the scFv of CAR-T cells contacts the target antigen, CAR-T cells proliferate, become activated, and secrete a large number of cytokines such as TNF-α, IL-1, IL-6, IFN-α, and IFN-γ to cause acute respiratory distress syndrome after binding to relevant antigens and multiple organ failure. (c) Off-target effects are the effect of cells on additional targets outside of the design, leading to autoimmune disease responses to normal tissues.
and hypoxia [3]. Two other studies have shown that severe CRS is associated with the activation or dysfunction of endothelial cells [26]. Available data indicate that VWF and Ang-2 elevate the levels of biomarkers of endothelial activation in severe CRS patients receiving CAR-T cell treatment [27]. The results of this study can help explain the mechanism by which tocilizumab alleviates CRS.

2.2. Neurologic Toxicity. CAR-T cell treatment of leukemia causes neurological symptoms, which is an unexpected and unclear phenomenon. Neurologic toxicity was very common in the CD19-specific CAR-T cell trial, but its pathogenesis was not very clear [28–30]. Several research groups have reported that these symptoms are diverse but minor symptoms can resolve on their own, such as paralysis, speech disorders, movement disorders, autism, and seizures [31, 32]. However, this unexpected toxicity can also cause death [33]. Previous studies showed that intravenous CAR-T cells were observed in cerebrospinal fluid, demonstrating that CAR-T cells can pass the blood-brain barrier, and that these CAR-T cells can be transported to the central nervous system to treat malignant nervous system tumors [28, 34, 35]. There is also evidence that the neurotoxicity may be caused by inflammatory cytokines leading to endothelial damage and inducing CAR-T cell-related encephalopathy syndrome (CRES) [31, 36]. Therefore, elevated cytokines may affect the central nervous system, and CAR-T cells may also affect brain tissue directly, causing a series of neurological side effects [37]. In addition, clinical studies have shown that the occurrence of neurologic toxicity is related to the premature peak concentrations of cytokines such as TNF-α, IL-6, and IFN-γ. High concentrations of secreted cytokines activate endothelial cells, resulting in increased levels of Ang-2 and VWF and leading to increased permeability of the blood-brain barrier [38, 39]. However, the mechanisms of these symptoms remain to be confirmed. Tocilizumab cannot effectively solve the problem of neurologic toxicity caused by CAR-T cells. Tocilizumab cannot cross the blood-brain barrier, but the CNS permeability of CAR-T cells is strong [40]. Therefore, corticosteroids have become the first-line treatment in some institutions for neurologic toxicity.

2.3. Off-Tumor Toxicity. After genetic modification, antigen receptors on the surface of T cells target tumor cells by identifying specific antigens on the surface of tumor cells [36]. However, these particular antigens may also be present in normal tissue cells, so the injection of CAR-T cells may damage normal tissues and organs, which is called the on-target/off-target tumor effect [41, 42].

The TAA recognized by CAR-T cells is not usually unique to tumor cells, and when CAR-T cells contact nontumor target antigens, it causes an off-target phenomenon. To avoid the off-target effect, double-antigen-reporting CAR-T cells have emerged. First, CAR-T cells recognize tumor cell antigen A and activate the expression of intracellular CAR-encoding sequences. After CAR expression, the surface single-chain antibody recognizes antigen B, thereby preventing CAR-T cells from killing tumor cells.

3. Advances in Research of CAR-T Cell Therapy for Solid Tumors

CAR-T cells have had a remarkable success in the treatment of hematological tumors, but there are some difficulties still in the treatment of solid tumors. When CAR-T cells are used to treat solid tumors, we face three main challenges: (1) lack of proper targets and heterogeneity, (2) CAR-T cells are not effectively infiltrating into tumor tissue, and (3) effect of tumor microenvironment on CAR-T cell therapy [43]. Table 1 lists several difficulties and solutions for the application of CAR-T cell therapy to solid tumors. Although early CAR-T cell trials of solid tumors did not show the same success as observed in leukemia trials, a better understanding of the multiple barriers seen in solid tumors could promote the design of clinical trials for CAR-T cells. In this early stage of clinical development, CAR-T cells offer much hope. The ability of genetic manipulation techniques to modify CAR-T cells provides almost unlimited opportunities for other changes and improvements, thus providing a strong desire for future success [3].

3.1. Lack of Proper Targets and Heterogeneity. Having an ideal target is one of the critical reasons why CAR-T cell therapy has achieved impressive results in hematological tumors; however, this is also the most significant obstacle to the CAR-T cell treatment for solid tumors [44]. Compared with hematological tumors, solid tumor tissues are more complex, and the protein expression profiles of different tumor cells vary.

### Table 1: Treatment and challenge of CAR-T cell therapy in the treatment of solid tumors.

| Clinical challenges                        | Strategy                                                                 | Expected outcome                                           |
|--------------------------------------------|--------------------------------------------------------------------------|------------------------------------------------------------|
| Lack of specific targets [44]              | Designed an antigen-specific inhibitory CAR-T molecule and a dual target CAR-T cells [48, 94] | Achieving dynamic and safe regulation of CAR-T cells [49] |
| CAR-T cell cannot effectively migrate and infiltrate tumor tissue [44] | Overexpression of HPSE in CAR-T cells can effectively degrade extracellular matrix and effectively infiltrate tumor tissue | Applied to solid tumor treatment [94]                      |
| Effect of tumor microenvironment on CAR-T cell therapy [44] | Specific blocking of immune checkpoint inhibition [48, 49, 94] | Improving the therapeutic effect of CAR-T cells in solid tumor [48, 94] |
| Tumor heterogeneity [52]                  | Expanding the scope of CAR-T cell therapy targeting tumor cells          | Reduce tumor cells to immune response without immune response or low response to immune escape |
It is difficult to select targets that can cover all tumor cells [45]. Importantly, studies have shown that even if antigen-positive tumor cells are cleared, a large number of antigen-negative cells still remain in the body, resulting in an especially high rate of tumor recurrence [46]. Solid tumor cells are derived from healthy tissues. Most antigens that are highly expressed in tumor cells are also expressed in small amounts in healthy cells, so it is challenging to avoid the nonspecific killing of normal cells, which produces on-target, off-tumor side effects [43]. A similar effect can also be observed in CAR-T cell therapy with CD19 as the target antigen. A way to address the safety of CAR-T cell therapy is to reduce the receptor affinity [47]. Another potential solution is to use multivalent CAR-T cells to reduce the binding of CAR-T cells to the target on healthy tissues [48–50]. Another challenge for CAR-T cell treatment in solid tumors is high tumor heterogeneity, in which tumors in the patient do not all express the same tumor-associated antigen [51]. Therefore, if a single target is recognized CAR-T cells is used to treat a solid tumor, theoretically, the heterogeneity of the solid tumor determines whether the therapy will be successful or fail to eradicate the disease [48, 49]. A feasible way to address tumor heterogeneity is to design multivalent CAR-T cells using genetic engineering techniques. Another necessary method to address tumor heterogeneity is to target cancer stem cells, which are highly correlated with tumor heterogeneity. CD133 is a novel tumor stem cell marker that has been overexpressed in many solid tumors and is now a target tumor marker for CAR-T cells [52]. The high heterogeneity of solid tumors makes their treatment much more difficult than the treatment of hematological malignancies. Therefore, the critical challenge for the treatment of solid tumors with CAR-T cells therapy is whether the appropriate target is selection [53].

3.2. CAR-T Cells Are Not Effectively Infiltrating into Tumor Tissue. Because CAR-T cells return to the lymphatic system as well as the blood system, there is a greater chance of contact with blood tumor cells. CAR-T cell therapy for solid tumors is more limited than hematological tumors, depending on whether it can penetrate into the tumor tissue through vascular endothelial cells [54]. Tumor tissue has a mechanism to downregulate the secretion of vascular-related factors. For example, the expression of the endothelin B receptor in tumor tissues is usually high, while the highly expressed endothelin B receptor downregulates the expression of ICAM-1 and inhibits the escape of T cells from blood vessels [55]. After the cells penetrate the vessel wall, they must penetrate the dense tumor tissue to bind to the target cells. It is also worth noting that the migration of CAR-T cells in solid tumors mainly depends on chemokine regulation. However, the expression of these important chemokines in tumors is usually low, such as chemokine ligand-11, factor-10, and chemokine ligand-12 [56, 57].

The low ability of CAR-T cells to migrate and invade tumors is due to the dense fibrotic matrix in solid tumors and downregulate the expression of chemokines that mediate T cell infiltration into tumor tissues [44, 53]. To achieve effective infiltration of tumor tissue by CAR-T cells, the researchers searched for CAR-T cells that coexpress better-matched chemokine receptors [58]. Oncolytic viruses with chemokines also increase the infiltration capacity of CAR-T cells, which have the ability to specifically infect and lyse tumor cells [59]. Stasi et al. used a subcutaneous lymphoma model to confirm that lymphoma cells expressing the chemokine CCL17 or CCL2 can effectively recruit CAR-T cells expressing CCR4, thereby achieving tumor killing of tumors [60]. Indeed, CAR-T cells expressing high levels of CCR2 receptor can migrate more efficiently to tumor sites secreting CCL2 and have stronger antitumor activity [58, 61]. In addition, the overexpression of HPS in CAR-T cells can effectively degrade extracellular matrix and effectively infiltrate tumor tissue. Another strategy can be implemented to increase the infiltration of T cells into tumor, to achieve the goal of increasing cells in the tumor that induce local inflammatory conditions using conventional cancer treatment methods such as radiotherapy and chemotherapy [62].

3.3. Effect of Hostile Immunosuppressive Tumor Microenvironment on CAR-T Cell Therapy. The tumor microenvironment (TME) is a complex tumor-dependent environment composed mainly of various extracellular matrices (ECMs) and stromal cells, inflammatory cells, and vasculature. Compared with that of hematological tumors, the tumor microenvironment of solid tumors is mostly characterized by low vascularization, hypoxia, and high concentration of extracellular matrix [63]. One of the possible reasons for the unsatisfactory effect of CAR-T cells in solid tumors in vivo is that T cells cannot penetrate these physical barriers and metabolic barriers formed by the TME around tumor tissues recruit immunosuppressive cells [64]. It is worth mentioning that the expression of activators is low in the tumor microenvironment, resulting in inhibition of activation and persistence of engineered T cells [65]. This causes blockade of CAR-T cell migration and immune escape of some tumor cells. Therefore, TME can be modified to improve the therapeutic effect of CAR-T cells in solid tumors [66]. Chemotherapy with cyclophosphamide alone or in combination with fludarabine facilitates T cell implantation and reduces inhibitory immune cells in TME [67].

Currently, clinical trials specifically blocking PD-1 and using CAR-T cell therapy are underway. Tumor cells overexpressing PD-L1 and PD-L2 reduce the tumor suppression mediated by CAR-T cells, thereby increasing tumor cell survival [62]. Targeting immunosuppressive pathways in the TME can cause a sustained antitumor response in advanced-stage patients, with an unusual effect on cancer progression. Studies have shown that specific blockade of PD-1 immunosuppression can effectively enhance CAR-T cell therapy, which is of considerable significance to potentially improving the therapeutic effect of this method in cancer patients [68, 69]. In addition to combining CAR-T cells with checkpoint inhibitors, researchers are also developing alternative therapies that block these inhibitory pathways [70–72].
4. Preclinical Studies of CAR-T Cell Immunotherapy

The results of first generation of CAR-T cell therapy in cancer treatment are not satisfactory. However, CAR-T cells targeting the CD19 antigen show good prospects and these CAR-T cells have had intriguing effect in clinical trials [34, 73, 74]. Several key features of CD19 make it a near-ideal therapeutic target: the CD19 antigen is expressed explicitly on the surface of the B cell lineage and B cell malignancies and not on the surface of normal hematopoietic stem cells [75, 76]. The CD19 CAR-T cells of the clinical trial are summarized in Table 2. Clinical studies at several different institutions have used CD19 CAR-T cell therapy in children and adults with recurrent B cell acute lymphoblastic leukemia (B-ALL), B cell non-Hodgkin’s lymphoma (B-NHL), and chronic lymphocytic leukemia (CLL), and these studies showed high antitumor treatment efficacy [77, 78]. As of August 2017, there were approximately 200 clinical trials involving CAR-T cells worldwide [79]. In those trials, approximately about 65% of the trials involved hematological malignancies, of which 80% involved CD19 CAR-T cells targeting B cell cancers [80-82]. Over the past year, more than 200 clinical trials have been conducted worldwide, including trials in liver cancer, breast cancer, neuroblastoma, pancreatic cancer, and glioblastoma [83].

The first-to-market CAR-T cell therapy Kymriah was approved by the FDA in October 2017 [79]. According to the results of clinical trials, Kymriah has a remission rate of 85% after three months when used to treat B cell acute lymphoblastic leukemia (B-ALL). However, 49% of patients develop side effects such as neurotoxicity and cytokine release syndrome, which are one of the causes of death in CAR-T cell therapy [46]. Then, the FDA approved a second CAR-T cell therapy, Yescarta, in October 2010 [70, 79]. Recent reports have proven that Yescarta is secure and controllable over the long term. After two years of follow-up of 101 patients with refractory large B cell lymphoma, a median follow-up of 27.1 months, 39% of patients maintained remission, and 37% of patients maintained complete remission. At two years, the overall survival rate is still 51%. In addition, 93% of patients with remission maintained remission at two years. Data analysis of the 108 patients at two years revealed that there were 12 patients (11%) and 35 patients (32%) with tertiary or higher cytokine syndrome and neurotoxicity, respectively, but these symptoms were overall controllable [28]. Four patients developed serious adverse reactions that were not associated with Yescarta. No new CRS or neurological even or death occurred.

5. The Opportunities and Challenges of CAR-T Cells

Although CAR-T cell therapy has been effective in a variety of cancers, there are still some challenges. Currently, to overcome the restrictions of CAR-T cell monotherapy, scientists have attempted to combine CAR-T cells with other therapies to improve the effectiveness of CAR-T cells. Numerous recent reports indicate that the combination of CAR-T cells and chemotherapy can decrease the side effects of the disease, enhance tumor antigen recognition, and increase the efficacy and persistence of CAR-T cells [84-86]. Additionally, studies have shown that the combination of CAR-T cells and radiation therapy can also enhance the efficacy of CAR-T cells. Weiss et al. demonstrated that combined radiotherapy and CAR-T cell therapy could improve the transport and infiltration of T cells, produce synergistic activity, improve tumor antigen presentation, and enhance the durability of CAR-T cells [87]. Some patients will experience antigen escape after receiving CAR-T cell therapy, leading to the failure of CAR-T cells and the recurrence of malignant tumor. The combination of CAR-T cells and checkpoint inhibitor therapy can effectively address this problem and improve this clinical outcome [88]. Current combinations of CAR-T cells and checkpoint inhibitors are effective in mice [88].

Other new attempts include introducing suicide genes or molecular switches, developing multitarget CAR-T cell technologies, resolving potential insertion-related mutations and improving long-term safety by using a nonintegrated lentiviral vector, and generating CAR-T cells with CRISPR/cas9 technology [89]. These gene editing strategies knock out the endogenous TCR and MHC molecules of the transfused CAR-T cells to avoid the host immune rejection and improve the recognition efficiency of CAR-T cells. Current clinical studies have found that CAR-T cells are useful in the treatment of hematological malignancies. In the future, CAR-T cells will become one of the most critical methods in the treatment of hematological malignancies, but their safety and specificity need to be further improved.

6. Global Landscape of CAR-T Cell Therapy

In the era of genome-wide data and big data, with the development of technology, more increasing numbers of data are accumulating. CAR-T cells are one of the most critical advances in the field of immunotherapy at the beginning of this century and will probably become an essential immunological technology in the 21st century, ultimately defeat fatal diseases such as cancer.

At present, CAR-T cells are widely used in cellular immunotherapy for various tumors. According to statistics, more than 300 clinical trials of CAR-T cell therapies have been approved by many national drug regulatory agencies, including the FDA of the United States [90, 91]. Statistical data from these clinical trials show that although the effects of various clinical trials vary due to the use of different sources and the preparation techniques of CARs and T cells, as well as differences in pretreatment and combinations of drugs, overall, CAR-T cells are effective in treating tumors with an effective rate of 30% to 70% or even more than 90%. For example, the complete remission rate for r/r ALL treated with the Novartis drug CTL019, which the FDA has approved, is 93%. Perhaps CAR-T cell therapy will ultimately remedy the fate of human cancer.

In the development of CAR-T cell therapy, China and the United States are pioneers. Globally, the number of clinical studies of CAR-T cell treatment is increasing dramatically [36]. According to statistics from the Cancer Research Institute of the United States, the number of CAR-T cell clinical trials continues to increase year by year. In the United States, the number of CAR-T cell clinical trials has been increasing significantly. The number of CAR-T cell clinical trials in China has increased significantly in recent years, and China has launched more CAR-T cell clinical trials than any other country in the world.
### Table 2: CD19 CAR-T of clinical trial.

| Study (reference) | Patient number | scFv       | Costimulatory domain | Median age (range) (y) | CAR-T cell doses | Disease-related outcomes |
|-------------------|----------------|------------|----------------------|------------------------|------------------|--------------------------|
| Maude et al. (2014) [28] | 30 ALL (25 children, 5 adults) | FMC63 | 4-1BB | Pediatric ALL: 11 (5–22)  
Adult ALL: 57 (36–60) | $0.76 \times 10^6$ to $20.6 \times 10^6$ CAR + T cells/kg | 6-month EFS: 67%  
6-month OS: 78%  
CR: 90% (MRD-negative in 88% of those who achieved CR) |
| Brentjens et al. (2011) [81] | 8 CLL adults | SJ25C1 | CD28 | Adults CLL: 58 (67-48) | Cohort receiving no LDC:  
$1.2 \times 3.0 \times 10^7$ CAR + T cells/kg  
Cy cohort: $0.4 \times 1.0 \times 10^7$ CAR + T cells/kg | ORR: 1/8 (PR); two others with ≥2 months of SD, all in Cy cohort |
| Brudno et al. (2016) [80] | 5 ALL | FMC63 | CD28 | Adults ALL: 25 (20–68) | $5.2 \times 10^6$ CAR + T cells/kg | CR: 80% (4/5, all MRD-negative) |
| Kochenderfer et al. (2015) [82] | 5 CLL adults | FMC63 | CD28 | Adults CLL: 61 (48–68) | $1 \times 10^6$ CAR + T cells/kg | CR: 60% |
| Lee et al. (2014) [76] | 20 B-ALL | FMC63 | CD28 | Children and young adults: 15 (1-30) | Median total CTL019-cell:  
$5.00 \times 10^8$ to $5.00 \times 10^8$  
Median CTL019-cell:  
$5.79 \times 10^6$ cells/kg (range, $3.08 \times 10^6$ to $8.87 \times 10^6$ cells/kg) | CR at 6 months:  
(57%; 95% CI, 37 to 76)  
CR: 57% median of 28.6 months (range, 3.5 to 37.9) |
| Schuster et al. (2017) [18] | 28 lymphomas | FMC63 | 4-1BB | Adult patients | | |

EFS: event-free survival; CLL: chronic lymphocytic leukemia; CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease.
Institute (CRI), as of February 2018, a total of 404 CAR-T cell projects worldwide are in clinical trials, mainly led by researchers in China and the United States [92]. Among them, there are 171 clinical trials in the United States and 152 in China. In total, 79.95% of CAR-T cell-based trials worldwide occur in China and the United States, suggesting that these two countries are leading the way for global CAR-T cell immunotherapy [92]. At present, CAR-T cell projects in clinical research involve more than 47 targets. In terms of target distribution, clinical trials of CAR-T cell therapy mainly focus on CD19, CD20, CD22, GPC3, BCMA, and other popular targets. Clinical trials targeting CD19 accounted for more than 40% of the CAR-T cell trials in the United States. Previously, two CAR-T cell products approved by Novartis and Kite Pharma also targeted CD19, and subsequent products have targeted BCMA, CD22, CD30, and other targets [93]. Similar to that in the United States, the number of CAR-T cell clinical trials targeting CD19 in China is also over 40%. However, the second most common target of CAR-T cell clinical trials in the United States is BCMA of CD19, while the number of clinical trials targeting BCMA in China is less than targeting CD20, CD22, and GPC3, accounting for only 5%.

7. Conclusions

CAR-T cells have shown amazing promise strength in the treatment of hematological tumors; however, due to lack of a suitable antigen and the hostile immunosuppressive tumor microenvironment, CAR-T cells are not effective in infiltrating into tumor tissue. CAR-T cells also face many difficulties in solid tumors. Future treatment schemes for tumors must be built on the combination of immunotherapy-based treatment with other methods. In the future, adoptive cell therapy, microenvironmental modification, and immune blockade strategies should be combined. CAR-T cells are only the beginning of immunotherapy rather than the end.

Abbreviations

CAR-T: Chimeric antigen receptor T
ACT: Adoptive cell transfer therapy
TILs: Tumor-infiltrating lymphocytes
TCR: T cell receptor
MHC: Major histocompatibility complex
ITAM: Immunoreceptor tyrosine-based activation motif
FDA: Food and Drug Administration
TAA: Tumor-associated antigen
B-ALL: B cell acute lymphoblastic leukemia
CLL: Chronic lymphocytic leukemia
B-NHL: B cell non-Hodgkin’s lymphoma
CRS: Cytokine release syndrome
CRES: CAR-T-related encephalopathy syndrome
TME: Tumor microenvironment
scFv: Single-chain antibody fragment.

Conflicts of Interest

The authors declare no conflict of interest.

Authors’ Contributions

QZ conceptualized the study, performed the literature search, and drafted most of the manuscript. JP and XZ made the table. ZH and XZ wrote the section on clinical application of CAR-T and the global landscape. GW and JZ revised the article and directed the review to be more focused. SL checked the grammar of the manuscript. JM gave final approval for the article to be published. All authors read and approved the manuscript. Qingyang Zhang and Jieming Ping have contributed equally to this work.

Acknowledgments

This work was supported by the National Natural Science Foundation of China (81202115) and Doctoral Innovation Fund of the Shanghai Jiaotong University School of Medicine (No. BXJ201732).

References

[1] C. H. Ruhlmann, T. Z. Iversen, M. Okera et al., “Multinational study exploring patients’ perceptions of side-effects induced by chemo-radiotherapy,” Radiotherapy and Oncology, vol. 117, no. 2, pp. 333–337, 2015.
[2] L. A. Emens, P. A. Ascieto, P. K. Darcy et al., “Cancer immunotherapy: opportunities and challenges in the rapidly evolving clinical landscape,” European Journal of Cancer, vol. 81, pp. 116–129, 2017.
[3] C. H. June, R. S. O’Connor, O. U. Kawalekar, S. Ghassemi, and M. C. Milone, “CAR T cell immunotherapy for human cancer,” Science, vol. 359, no. 6382, pp. 1361–1365, 2018.
[4] K. Gowrishankar, L. Birtwistle, and K. Micklethwaite, “Manipulating the tumor microenvironment by adoptive cell transfer of CAR T-cells,” Mammalian Genome, vol. 29, no. 11-12, pp. 739–756, 2018.
[5] Y. C. Lu, X. Yao, J. S. Crystal et al., “Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions,” Clinical Cancer Research, vol. 20, no. 13, pp. 3401–3410, 2014.
[6] Y. Najima, M. Tomizawa-Murasawa, Y. Saito et al., “Induction of WT1-specific human CD8+ T cells from human HSCs in HLA class I Tg NOD/SCID/IL2rgKO mice,” Blood, vol. 127, no. 6, pp. 722–734, 2016.
[7] T. Chodon, B. Comin-Anduix, B. Chmielewski et al., “Adaptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma,” Clinical Cancer Research, vol. 20, no. 9, pp. 2457–2465, 2014.
[8] D. M. Barrett, S. A. Grupp, and C. H. June, “Chimeric antigen receptor- and TCR-modified T cells enter main street and wall street,” Journal of Immunology, vol. 195, no. 3, pp. 755–761, 2015.
[9] J. A. Figueroa, A. Reidy, L. Mirandola et al., “Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy,” International Reviews of Immunology, vol. 34, no. 2, pp. 154–187, 2015.
[10] C. Heuser, A. Hombach, C. Losch, K. Manista, and H. Abken, “T-cell activation by recombinant immunoreceptors: impact of the intracellular signalling domain on the stability of receptor expression and antigen-specific activation of grafted T cells,” Gene Therapy, vol. 10, no. 17, pp. 1408–1419, 2003.
[11] T. Brocker and K. Karjalainen, “Signals through T cell receptor-zeta chain alone are insufficient to prime resting T lymphocytes,” The Journal of Experimental Medicine, vol. 181, no. 5, pp. 1653–1659, 1995.

[12] S. Wilkie, G. Picco, J. Foster et al., “Retargeting of human T cells to tumor-associated MUC1: the evolution of a chimeric antigen receptor,” Journal of Immunology, vol. 180, no. 7, pp. 4901–4909, 2008.

[13] M. C. Ramello, I. Benzaid, B. M. Kuenzi et al., “An immuno-proteomic approach to characterize the CAR interactome and signalosome,” Science Signaling, vol. 12, no. 568, article eaap9777, 2019.

[14] M. Chmielowski and H. Abken, “TRUCKs: the fourth generation of CARs,” Expert Opinion on Biological Therapy, vol. 15, no. 8, pp. 1145–1154, 2015.

[15] M. Kalaitsidou, G. Kueberuwa, A. Schutt, and D. E. Gilham, “T cells to tumor-associated MUC1: the evolution of a chimeric antigen receptor,” Journal of Immunology, vol. 180, no. 7, pp. 4901–4909, 2008.

[16] S. A. Rosenberg, B. S. Packard, P. M. Aebersold et al., “Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report,” The New England Journal of Medicine, vol. 319, no. 25, pp. 1676–1680, 1988.

[17] R. A. Gardner, O. Finney, C. Annesley et al., “Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults,” Blood, vol. 129, no. 25, pp. 3322–3331, 2017.

[18] S. J. Schuster, J. Svoboda, E. A. Chong et al., “Chimeric antigen receptor T cells in refractory B-cell lymphomas,” The New England Journal of Medicine, vol. 377, no. 26, pp. 2545–2554, 2017.

[19] J. N. Brudno and J. N. Kochenderfer, “Toxicities of chimeric antigen receptor T cells: recognition and management,” Blood, vol. 127, no. 26, pp. 3321–3330, 2016.

[20] K. A. Hay, L. A. Hanafi, D. Li et al., “Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy,” Blood, vol. 130, no. 21, pp. 2295–2306, 2017.

[21] S. S. Neelapu, F. L. Locke, N. L. Bartlett et al., “Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma,” The New England Journal of Medicine, vol. 377, no. 26, pp. 2531–2544, 2017.

[22] A. Shimabukuro-Vornhagen, P. Güdel, M. Subklewe et al., “Cytokine release syndrome,” Journal for Immunotherapy of Cancer, vol. 6, no. 1, p. 56, 2018.

[23] C. A. Hunter and S. A. Jones, “IL-6 as a keystone cytokine in health and disease,” Nature Immunology, vol. 16, no. 5, pp. 448–457, 2015.

[24] F. O. Martinez, L. Helming, and S. Gordon, “Alternative activation of macrophages: an immunologic functional perspective,” Annual Review of Immunology, vol. 27, no. 1, pp. 451–483, 2009.

[25] T. Giavridis, S. J. C. van der Stegen, J. Eyquem, M. Hamieh, A. Piersigilli, and M. Sadelain, “CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade,” Nature Medicine, vol. 24, no. 6, pp. 731–738, 2018.

[26] A. E. Obstfeld, N. V. Frey, K. Mansfield et al., “Cytokine release syndrome associated with chimeric-antigen receptor T-cell therapy: clinicopathological insights,” Blood, vol. 130, no. 23, pp. 2569–2572, 2017.

[27] D. W. Lee, R. Gardner, D. L. Porter et al., “Current concepts in the diagnosis and management of cytokine release syndrome,” Blood, vol. 124, no. 2, pp. 188–195, 2014.

[28] S. L. Maude, N. Frey, P. A. Shaw et al., “Chimeric antigen receptor T cells for sustained remissions in leukemia,” The New England Journal of Medicine, vol. 371, no. 16, pp. 1507–1517, 2014.

[29] J. Pan, J. F. Yang, B. P. Deng et al., “High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients,” Leukemia, vol. 31, no. 12, pp. 2587–2593, 2017.

[30] Z. Wang, Y. Guo, and W. Han, “Current status and perspectives of chimeric antigen receptor modified T cells for cancer treatment,” Protein & Cell, vol. 8, no. 12, pp. 896–925, 2017.

[31] V. Prudent and W. S. Breitbart, “Chimeric antigen receptor T-cell neoplastic toxicities in acute lymphoblastic leukemia,” Palliative & Supportive Care, vol. 15, no. 4, pp. 499–503, 2017.

[32] J. Gust, K. A. Hay, L. A. Hanafi et al., “Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells,” Cancer Discovery, vol. 7, no. 12, pp. 1404–1419, 2017.

[33] J. Abbasi, “Amid FDA approval filings, another CAR-T therapy patient death,” JAMA, vol. 317, no. 22, article 2271, 2017.

[34] R. J. Brentjens, M. L. Davila, I. Riviere et al., “CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia,” Science Translational Medicine, vol. 5, no. 177, article 177ra38, 2013.

[35] J. S. Abramson and Y. B. Chen, “More on anti-CD19 CAR T cells in CNS diffuse large-B-cell lymphoma,” The New England Journal of Medicine, vol. 377, no. 21, article 2102, 2017.

[36] Y. Leyfman, “Chimeric antigen receptors: unleashing a new age of anti-cancer therapy,” Cancer Cell International, vol. 18, no. 1, p. 182, 2018.

[37] C. L. Mackall and D. B. Miklos, “CNS endothelial cell activation emerges as a driver of CAR T cell-associated neurotoxicity,” Cancer Discovery, vol. 7, no. 12, pp. 1371–1373, 2017.

[38] Y. Hu, J. Sun, Z. Wu et al., “Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy,” Journal of Hematology & Oncology, vol. 9, no. 1, p. 70, 2016.

[39] H. Kometani, M. Kawatani, G. Ohta et al., “Marked elevation of interleukin-6 in mild encephalopathy with a reversible splenial lesion (MERS) associated with acute focal bacterial nephritis caused by Enterococcus faecalis,” Brain & Development, vol. 36, no. 6, pp. 551–553, 2014.

[40] B. D. Santomasso, J. H. Park, D. Salloum et al., “Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia,” Cancer Discovery, vol. 8, no. 8, pp. 958–971, 2018.

[41] R. A. Morgan, J. C. Yang, M. Kitano, M. E. Dudley, C. M. Laurencot, and S. A. Rosenberg, “Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2,” Molecular Therapy, vol. 18, no. 4, pp. 843–851, 2010.

[42] J. H. Sampson, A. B. Heimberger, G. E. Archer et al., “Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma,” Journal of Clinical Oncology, vol. 28, no. 31, pp. 4722–4729, 2010.
L. Springuel, C. Lonez, B. Alexandre et al., “Chimeric antigen receptor-T cells for targeting solid tumors: current challenges and existing strategies,” BioDrugs, vol. 33, no. 5, pp. 515–537, 2019.

Z. Wang, Z. Wu, Y. Liu, and W. Han, “New development in CAR-T cell therapy,” Journal of Hematology & Oncology, vol. 10, no. 1, p. 53, 2017.

H. Shen and P. W. Laird, “Interplay between the cancer genome and epigenome,” Cell, vol. 153, no. 1, pp. 38–55, 2013.

S. Wilkie, M. C. I. van Schalkwyk, S. Hobbs et al., “Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling,” Journal of Clinical Immunology, vol. 32, no. 5, pp. 1059–1070, 2012.

C. C. Kloss, M. Condomines, M. Bachmann, and M. Sadelan, “Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells,” Nature Biotechnology, vol. 31, no. 1, pp. 71–75, 2013.

H. G. Caruso, L. V. Hurton, A. Najjar et al., “Tuning sensitivity of CAR to EGFR density limits recognition of normal tissue while maintaining potent antitumor activity,” Cancer Research, vol. 75, no. 17, pp. 3505–3518, 2015.

S. Kakarla and S. Gottschalk, “CAR T cells for solid tumors: armed and ready to go?,” Cancer Journal, vol. 20, no. 2, pp. 151–155, 2014.

S. J. Bagley and D. M. O’Rourke, “Clinical investigation of CAR T cells for solid tumors: lessons learned and future directions,” Pharmacology & Therapeutics, vol. 205, article 107419, 2019.

K. Newick, S. O’Brien, E. Moon, and S. M. Albelda, “CAR T cell therapy for solid tumors,” Annual Review of Medicine, vol. 68, pp. 139–152, 2017.

H. Salomon, K. Franciszekiewicz, D. Damotte et al., “Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors,” The Journal of Clinical Investigation, vol. 122, no. 3, pp. 899–910, 2012.

Y. Vedvyas, J. E. McCloskey, Y. Yang et al., “Manufacturing and preclinical validation of CAR T cells targeting ICAM-1 for advanced thyroid cancer therapy,” Scientific Reports, vol. 9, no. 1, article 10634, 2019.

M. C. Poznansky, I. T. Olszak, R. H. Evans et al., “Thymocyte emigration is mediated by active movement away from stroma-derived factors,” The Journal of Clinical Investigation, vol. 109, no. 8, pp. 1101–1110, 2002.

M. C. Poznansky, I. T. Olszak, R. Foxall, R. H. Evans, A. D. Luster, and D. T. Scadden, “Active movement of T cells away from a chemokine,” Nature Medicine, vol. 6, no. 5, pp. 543–548, 2000.

J. A. Craddock, A. Lu, A. Bear et al., “Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b,” Journal of Immunotherapy, vol. 33, no. 8, pp. 780–788, 2010.
[74] D. L. Porter, B. L. Levine, M. Kalos, A. Bagg, and C. H. June, “Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia,” The New England Journal of Medicine, vol. 365, no. 8, pp. 725–733, 2011.

[75] M. C. van Zelm, I. Reisli, M. van der Burg et al., “An antibody-deficiency syndrome due to mutations in the CD19 gene,” The New England Journal of Medicine, vol. 354, no. 18, pp. 1901–1912, 2006.

[76] D. W. Lee, J. N. Kochenderfer, M. Stetler-Stevenson et al., “Doxorubicin elicits myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer,” Journal of Hematology & Oncology, vol. 6, no. 1, p. 166, 2013.

[77] K. C. Pehlivan, B. B. Duncan, and D. W. Lee, “Clinical trials of CAR-T cells in China,” Journal of Hematology & Oncology, vol. 10, no. 1, p. 166, 2017.

[78] A. L. Xia, X. C. Wang, Y. J. Lu, X. J. Lu, and B. Sun, “Chimeric antigen receptor T (CAR-T) cell therapy for solid tumors: challenges and opportunities,” Oncotarget, vol. 8, no. 52, pp. 90521–90531, 2017.

[79] V. D. Fedorov, M. Themeli, and M. Sadelain, “PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses,” Science Translational Medicine, vol. 5, no. 215, article 215ra172, 2013.